semaglutide als Full article: Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists Semaglutid als Add-on zu Neuroleptika?

215 High expression of NO is a characteristic of UC, and inhibition of the NF-B pathway can also inhibit the expression of IL-6 and iNOS, thereby reducing the content of NO and protecting the intestinal mucosa

(2015) Five Chinese patients with 5-oxoprolinuria due to glutathione synthetase and 5-oxoprolinase deficiencies, Brain Dev

Genes 11 , 424 (2020)

Global disease burden of conditions requiring emergency surgery

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide

Topline results announced in December 2025 were positive, showing that orforglipron maintained weight loss after the switch